E-viri
Recenzirano
Odprti dostop
-
Nguyen, Linh T.; Saibil, Samuel D.; Sotov, Valentin; Le, Michael X.; Khoja, Leila; Ghazarian, Danny; Bonilla, Luisa; Majeed, Habeeb; Hogg, David; Joshua, Anthony M.; Crump, Michael; Franke, Norman; Spreafico, Anna; Hansen, Aaron; Al-Habeeb, Ayman; Leong, Wey; Easson, Alexandra; Reedijk, Michael; Goldstein, David P.; McCready, David; Yasufuku, Kazuhiro; Waddell, Thomas; Cypel, Marcelo; Pierre, Andrew; Zhang, Bianzheng; Boross-Harmer, Sarah; Cipollone, Jane; Nelles, Megan; Scheid, Elizabeth; Fyrsta, Michael; Lo, Charlotte S.; Nie, Jessica; Yam, Jennifer Y.; Yen, Pei Hua; Gray, Diana; Motta, Vinicius; Elford, Alisha R.; DeLuca, Stephanie; Wang, Lisa; Effendi, Stephanie; Ellenchery, Ragitha; Hirano, Naoto; Ohashi, Pamela S.; Butler, Marcus O.
Cancer Immunology, Immunotherapy, 05/2019, Letnik: 68, Številka: 5Journal Article
Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion interleukin-2 (IL-2), for which high dose is standard. To assess a modified TIL protocol using lower dose IL-2, we performed a single institution phase II protocol in unresectable, metastatic melanoma. The primary endpoint was response rate. Secondary endpoints were safety and assessment of immune correlates following TIL infusion. Twelve metastatic melanoma patients were treated with non-myeloablative lymphodepleting chemotherapy, TIL, and low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9–10 doses over 2 weeks). All but one patient had previously progressed after treatment with immune checkpoint inhibitors. No unexpected adverse events were observed, and patients received an average of 6.8 doses of IL-2. By RECIST v1.1, two patients experienced a partial response, one patient had an unconfirmed partial response, and six had stable disease. Biomarker assessment confirmed an increase in IL-15 levels following lymphodepleting chemotherapy as expected and a lack of peripheral regulatory T-cell expansion following protocol treatment. Interrogation of the TIL infusion product and monitoring of the peripheral blood following infusion suggested engraftment of TIL. In one responding patient, a population of T cells expressing a T-cell receptor Vβ chain that was dominant in the infusion product was present at a high percentage in peripheral blood more than 2 years after TIL infusion. This study shows that this protocol of low-dose IL-2 following adoptive cell transfer of TIL is feasible and clinically active. (ClinicalTrials.gov identifier NCT01883323.)
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.